Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Mar;40(3):546–551. doi: 10.1128/aac.40.3.546

Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.

L E Bermudez 1, C B Inderlied 1, P Kolonoski 1, M Wu 1, L Barbara-Burnham 1, L S Young 1
PMCID: PMC163155  PMID: 8851568

Abstract

Levofloxacin, ofloxacin, and Bay Y 3118 are new fluoroquinolones with variable in vitro bacteriostatic and bactericidal activities against the Mycobacterium avium complex (MAC). The potential therapeutic activities of these agents both alone and combined with ethambutol were evaluated in a human macrophage test system and in the beige mouse animal test system with MAC strain 101. Bay Y 3118 at a human-equivalent dose of 30 mg/kg/day for 4 weeks caused a significant reduction in mortality compared with that in untreated controls (P = 0.02). Bay Y 3118 also caused significant reductions in the number of MAC organisms in the blood, liver tissue, and spleen tissue compared with those in untreated controls. Levofloxacin at a human-equivalent dose of 200 mg/kg/day was associated with a significant reduction in mortality (10 versus 39%); however, treatment with either levofloxacin or ofloxacin (200 mg/kg/day) did not result in significant reductions in the numbers of MAC organisms in blood, liver, and spleen compared with those in untreated controls. When Bay Y 3118 was combined with ethambutol, there was no enhancement in therapeutic activity except in the spleen in terms of CFU per gram (reductions of 89% compared with the untreated control, 63% compared with Bay Y 3118 alone, and 72.5% compared with ethambutol alone). Levofloxacin in combination with ethambutol was more active than either drug alone in the reduction of organisms in blood, liver, and spleen. Bay Y 3118 was the most active fluoroquinolone for monotherapy of MAC infection in beige mice, and the combination of ethambutol plus either levofloxacin or ofloxacin was at least additive. In summary, this study demonstrates that quinolones, although active, are inhibitory against MAC in vivo and that there is little correlation between the activity of quinolones in vitro and the activity in mice.

Full Text

The Full Text of this article is available as a PDF (223.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertram M. A., Inderlied C. B., Yadegar S., Kolanoski P., Yamada J. K., Young L. S. Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis. 1986 Jul;154(1):194–195. doi: 10.1093/infdis/154.1.194. [DOI] [PubMed] [Google Scholar]
  2. Bongaerts G. P., Hoogkamp-Korstanje J. A. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections. Antimicrob Agents Chemother. 1993 Sep;37(9):2017–2019. doi: 10.1128/aac.37.9.2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boyce S. T., Warden G. D., Holder I. A. Noncytotoxic combinations of topical antimicrobial agents for use with cultured skin substitutes. Antimicrob Agents Chemother. 1995 Jun;39(6):1324–1328. doi: 10.1128/aac.39.6.1324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chiu J., Nussbaum J., Bozzette S., Tilles J. G., Young L. S., Leedom J., Heseltine P. N., McCutchan J. A. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. Ann Intern Med. 1990 Sep 1;113(5):358–361. doi: 10.7326/0003-4819-113-5-358. [DOI] [PubMed] [Google Scholar]
  5. Dautzenberg B., Truffot C., Legris S., Meyohas M. C., Berlie H. C., Mercat A., Chevret S., Grosset J. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):564–569. doi: 10.1164/ajrccm/144.3_Pt_1.564. [DOI] [PubMed] [Google Scholar]
  6. Fernandes P. B., Hardy D. J., McDaniel D., Hanson C. W., Swanson R. N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother. 1989 Sep;33(9):1531–1534. doi: 10.1128/aac.33.9.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fu K. P., Lafredo S. C., Foleno B., Isaacson D. M., Barrett J. F., Tobia A. J., Rosenthale M. E. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):860–866. doi: 10.1128/aac.36.4.860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gangadharam P. R., Edwards C. K., 3rd, Murthy P. S., Pratt P. F. An acute infection model for Mycobacterium intracellulare disease using beige mice: preliminary results. Am Rev Respir Dis. 1983 May;127(5):648–649. doi: 10.1164/arrd.1983.127.5.648. [DOI] [PubMed] [Google Scholar]
  9. García I., Pascual A., Perea E. J. Intracellular penetration and activity of BAY Y 3118 in human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1994 Oct;38(10):2426–2429. doi: 10.1128/aac.38.10.2426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Garrelts J. C. Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. DICP. 1991 May;25(5):525–531. doi: 10.1177/106002809102500513. [DOI] [PubMed] [Google Scholar]
  11. Heifets L. B., Lindholm-Levy P. J. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle. 1987 Dec;68(4):267–276. doi: 10.1016/0041-3879(87)90067-5. [DOI] [PubMed] [Google Scholar]
  12. Inderlied C. B., Barbara-Burnham L., Wu M., Young L. S., Bermudez L. E. Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages. Antimicrob Agents Chemother. 1994 Aug;38(8):1838–1843. doi: 10.1128/aac.38.8.1838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Inderlied C. B., Kolonoski P. T., Wu M., Young L. S. In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex. J Infect Dis. 1989 May;159(5):994–997. doi: 10.1093/infdis/159.5.994. [DOI] [PubMed] [Google Scholar]
  14. Inderlied C. B., Young L. S., Yamada J. K. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother. 1987 Nov;31(11):1697–1702. doi: 10.1128/aac.31.11.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kaatz G. W., Seo S. M., Ruble C. A. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1993 May;37(5):1086–1094. doi: 10.1128/aac.37.5.1086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kemper C. A., Havlir D., Haghighat D., Dubé M., Bartok A. E., Sison J. P., Yao Y., Yangco B., Leedom J. M., Tilles J. G. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis. 1994 Jul;170(1):157–164. doi: 10.1093/infdis/170.1.157. [DOI] [PubMed] [Google Scholar]
  17. Kemper C. A., Meng T. C., Nussbaum J., Chiu J., Feigal D. F., Bartok A. E., Leedom J. M., Tilles J. G., Deresinski S. C., McCutchan J. A. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. Ann Intern Med. 1992 Mar 15;116(6):466–472. doi: 10.7326/0003-4819-116-6-466. [DOI] [PubMed] [Google Scholar]
  18. Klemens S. P., Cynamon M. H. In vivo activities of newer rifamycin analogs against Mycobacterium avium infection. Antimicrob Agents Chemother. 1991 Oct;35(10):2026–2030. doi: 10.1128/aac.35.10.2026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lemaire I. Characterization of the bronchoalveolar cellular response in experimental asbestosis. Different reactions depending on the fibrogenic potential. Am Rev Respir Dis. 1985 Jan;131(1):144–149. doi: 10.1164/arrd.1985.131.1.144. [DOI] [PubMed] [Google Scholar]
  20. Mor N., Vanderkolk J., Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother. 1994 May;38(5):1161–1164. doi: 10.1128/aac.38.5.1161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nichterlein T., Kretschmar M., Budeanu C., Bauer J., Linss W., Hof H. Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells. Antimicrob Agents Chemother. 1994 Jul;38(7):1501–1506. doi: 10.1128/aac.38.7.1501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rastogi N., Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother. 1991 Mar;35(3):462–470. doi: 10.1128/aac.35.3.462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Skinner P. S., Furney S. K., Kleinert D. A., Orme I. M. Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Mar;39(3):750–753. doi: 10.1128/AAC.39.3.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Tomioka H., Sato K., Saito H., Yamada Y. Susceptibility of Mycobacterium avium and Mycobacterium intracellulare to various antibacterial drugs. Microbiol Immunol. 1989;33(6):509–514. doi: 10.1111/j.1348-0421.1989.tb02000.x. [DOI] [PubMed] [Google Scholar]
  25. Yajko D. M., Sanders C. A., Nassos P. S., Hadley W. K. In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin. Antimicrob Agents Chemother. 1990 Dec;34(12):2442–2444. doi: 10.1128/aac.34.12.2442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Young L. S., Berlin O. G., Inderlied C. B. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med. 1987 Apr 27;82(4A):23–26. [PubMed] [Google Scholar]
  27. Young L. S., Wiviott L., Wu M., Kolonoski P., Bolan R., Inderlied C. B. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet. 1991 Nov 2;338(8775):1107–1109. doi: 10.1016/0140-6736(91)91965-w. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES